Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis.

@article{Manley2004AdvancesIT,
  title={Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis.},
  author={P. Manley and G. Bold and J. Br{\"u}ggen and G. Fendrich and P. Furet and J. Mestan and C. Schnell and B. Stolz and T. Meyer and B. Meyhack and W. Stark and A. Strauss and J. Wood},
  journal={Biochimica et biophysica acta},
  year={2004},
  volume={1697 1-2},
  pages={
          17-27
        }
}
Initial studies with angiogenesis inhibitors showed little clinical benefit. However, recently reported clinical studies in colorectal cancer have shown that bevacizumab, a vascular endothelial growth factor (VEGF) monoclonal antibody, in combination with cytotoxic therapy has positive effects on patient survival. Furthermore, the VEGF receptor kinase (VEGF-R) tyrosine kinase inhibitor, vatalanib, has also shown encouraging results in colorectal cancer, with molecular resonance imaging… Expand
Angiogenesis inhibitors in the treatment of cancer
Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors.
Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 43 REFERENCES
VEGF-Trap: A VEGF blocker with potent antitumor effects
  • J. Holash, S. Davis, +16 authors J. Rudge
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 2002
Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
  • B. Kuenen, J. Tabernero, +10 authors A. Harris
  • Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2003
...
1
2
3
4
5
...